The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has won U.S. Food and Drug Administration approval for RYBREVANT FASPRO, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback